Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance

Summary

This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease and impaired glucose tolerance. Patients will receive either azeliragon or placebo with a patient's participation lasting approximately 9 months (in Part 1) or 21 months (in Part 2).

Timeline

Start

2019-06-27

Primary completion

2020-12-01

Completion

2021-01-29

Drugs

Indications